224 related articles for article (PubMed ID: 25633268)
1. Evaluation of plasma MMP-8, MMP-9 and TIMP-1 identifies candidate cardiometabolic risk marker in metabolic syndrome: results from double-blinded nested case-control study.
Hoseini SM; Kalantari A; Afarideh M; Noshad S; Behdadnia A; Nakhjavani M; Esteghamati A
Metabolism; 2015 Apr; 64(4):527-38. PubMed ID: 25633268
[TBL] [Abstract][Full Text] [Related]
2. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
[TBL] [Abstract][Full Text] [Related]
3. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
4. Inflammations mediators and circulating levels of matrix metalloproteinases: Biomarkers of diabetes in Tunisians metabolic syndrome patients.
Zayani Y; El Golli N; Zidi W; Guizani I; Boussairi S; Aloui S; Ayadi I; Ftouhi B; Feki M; Ben Romdhane N; Ben Sliman H; Allal-Elasmi M; Kaabachi N
Cytokine; 2016 Oct; 86():47-52. PubMed ID: 27455450
[TBL] [Abstract][Full Text] [Related]
5. Serum tissue-degrading proteinases and incident cardiovascular disease events.
Tuomainen AM; Kormi I; Havulinna AS; Tervahartiala T; Salomaa V; Sorsa T; Pussinen PJ
Eur J Prev Cardiol; 2014 Jul; 21(7):806-12. PubMed ID: 23079500
[TBL] [Abstract][Full Text] [Related]
6. Gelatinases and their tissue inhibitors in a group of subjects with metabolic syndrome.
Hopps E; Lo Presti R; Montana M; Noto D; Averna MR; Caimi G
J Investig Med; 2013 Aug; 61(6):978-83. PubMed ID: 23661104
[TBL] [Abstract][Full Text] [Related]
7. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
[TBL] [Abstract][Full Text] [Related]
8. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
Marcaccini AM; Novaes AB; Meschiari CA; Souza SL; Palioto DB; Sorgi CA; Faccioli LH; Tanus-Santos JE; Gerlach RF
Clin Chim Acta; 2009 Nov; 409(1-2):117-22. PubMed ID: 19751716
[TBL] [Abstract][Full Text] [Related]
9. Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease.
Cicero AF; Derosa G; Manca M; Bove M; Borghi C; Gaddi AV
Endothelium; 2007; 14(4-5):193-8. PubMed ID: 17922335
[TBL] [Abstract][Full Text] [Related]
10. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum MMP-9/TIMP-1 ratio in patients with homozygous familial hypercholesterolemia: effects of LDL-apheresis.
Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Halvorsen B; Ose L; Aukrust P; Holven KB
Cytokine; 2013 Jan; 61(1):194-8. PubMed ID: 23131422
[TBL] [Abstract][Full Text] [Related]
12. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
[TBL] [Abstract][Full Text] [Related]
13. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
Pawlak K; Pawlak D; Mysliwiec M
Cytokine; 2005 Jul; 31(1):18-24. PubMed ID: 15896974
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors.
Tedeschi A; Asero R; Lorini M; Marzano AV; Cugno M
Clin Exp Allergy; 2010 Jun; 40(6):875-81. PubMed ID: 20214668
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
16. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
17. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
18. Oxidized low-density lipoprotein, matrix-metalloproteinase-8 and carotid atherosclerosis in spinal cord injured subjects.
Paim LR; Schreiber R; Matos-Souza JR; Silva AA; Campos LF; Azevedo ER; Alonso K; de Rossi G; Etchebehere M; Gorla JI; Cliquet A; Nadruz W
Atherosclerosis; 2013 Dec; 231(2):341-5. PubMed ID: 24267248
[TBL] [Abstract][Full Text] [Related]
19. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
20. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
Głowińska-Olszewska B; Urban M
Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
